Feasibility and safety of the vNOTES approach in patients with concomitant endometriosis: a prospective study of 105 consecutive cases
article
OA: hybrid
CC0
Abstract
INTRODUCTION: This study evaluates the surgical feasibility, safety and early perioperative outcomes of Transvaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) for benign gynecological conditions in patients with histologically confirmed concomitant endometriosis.
METHODS: This prospective, single-center cohort study evaluated 105 consecutive patients who underwent vNOTES for benign gynecological pathologies with concomitant endometriosis at Valais Hospital between June 2021 and June 2025. Exclusion criteria included a negative "sliding sign", known or suspected posterior deep infiltrating endometriosis (DIE), and a history of major pelvic surgery or pelvic radiotherapy. Data analyzed included demographic characteristics, intraoperative details (e.g., rASRM score, operative time, estimated blood loss, Clavien-Dindo complications, length of stay).
RESULTS: The mean age was 46.2 ± 11.2 years, and the mean body mass index was 26.2 ± 5.5 kg/m2. Among the 105 patients included, a history of endometriosis was present in 34 (32.4%) patients. Mean operative time and blood loss were 57.3 ± 26.1 min and 61.9 ± 69 mL, respectively. Intraoperative complications occurred in 4 patients (3.8%), while postoperative complications were observed in 24 (22.9%), most commonly cystitis (n = 7, 6.7%) and surgical site infections (n = 6, 5.7%). According to the Clavien-Dindo classification, 21 patients (20.0%) experienced Grade II complications and 3 patients (2.9%) had Grade III. The conversion rate to conventional laparoscopy was 3.8% (n = 4). The mean hospital stay was 1.9 days. According to the rASRM classification, 60 patients (57.1%) were Stage I, 32 (30.5%) Stage II, 9 (8.6%) Stage III, and 4 (3.8%) Stage IV.
CONCLUSION: The vNOTES approach is a feasible and safe alternative to conventional laparoscopy for patients with benign gynecological conditions and concomitant endometriosis in the absence of preoperative evidence of severe posterior compartment involvement and pouch of Douglas obliteration.
My notes (saved in your browser only)
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (25)
- A systematic review on the prevalence of endometriosis in women via openalex
- Impact of endometriosis on surgical outcomes and complications of total laparoscopic hysterectomy via openalex
- Keep your attention closer to the ureters: Ureterolysis in deep endometriosis surgery via openalex
- Robot-assisted Transvaginal Natural Orifice Transluminal Endoscopic Surgery for Management of Endometriosis: A Pilot Study of 33 Cases via openalex
- Robot-Assisted Vaginal Natural Orifice Transluminal Endoscopic Surgery (RvNOTES) With Total Hysterectomy for Management of Stage IV Endometriosis With/Without Complete Cul-de-Sac Obliteration: 23-Case Pilot Feasibility Study via openalex
- Stage-Specific outcomes of robotic transvaginal NOTES hysterectomy in endometriosis: A comparative study via openalex
- W4214754424 via openalex
- W4295067559 via openalex
- W4313647763 via openalex
- W1983491220 via openalex
- W4387953380 via openalex
- W4402711244 via openalex
- W4402841945 via openalex
- W4403044811 via openalex
- W4404460397 via openalex
- W4407756877 via openalex
- W4408812481 via openalex
- W4412492872 via openalex
- W4412536948 via openalex
- W4386151640 via openalex
- W2096998881 via openalex
- W2593318548 via openalex
- W2969517110 via openalex
- W3112817504 via openalex
- W4206943890 via openalex
Source provenance
- openalex
- last seen: 2026-10-01T06:07:16.299885+00:00
- pubmed
- last seen: 2026-10-01T06:08:47.957859+00:00
License: CC0
· commercial use OK